

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE

ARBUTUS BIOPHARMA CORPORATION)	
and GENEVANT SCIENCES GmbH,)	
)	
Plaintiffs,)	
)	
v.)	C.A. No. 22-252 (MSG)
)	
MODERNA, INC. and MODERNATX, INC.)	REDACTED - PUBLIC VERSION
)	
Defendants.)	

**DEFENDANTS' BRIEF IN SUPPORT OF THEIR MOTION TO SEAL
PORTIONS OF PLAINTIFFS' MOTION TO COMPEL (D.I. 184)**

OF COUNSEL:

Patricia A. Carson, Ph.D.
Jeanna M. Wacker, P.C.
Mark C. McLennan
Yan-Xin Li
Caitlin Dean
Nancy Kaye Horstman
Shaoyao Yu
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, NY 10022
(212) 446-4800

Alina Afinogenova
KIRKLAND & ELLIS LLP
200 Clarendon Street
Boston, MA 02116
(617) 385-7500

Yan-Xin Li
KIRKLAND & ELLIS LLP
555 California Street, 27th Floor
San Francisco, CA 94104
(415) 439-1400

MORRIS, NICHOLS, ARSHT & TUNNELL LLP
Jack B. Blumenfeld (#1014)
Brian P. Egan (#6227)
Travis J. Murray (#6882)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
began@morrisnichols.com
tmurray@morrisnichols.com

Attorneys for Defendants

Original filing date: January 12, 2024
Redacted filing date: January 16, 2024

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. LEGAL STANDARD.....	1
III. ARGUMENT	2
IV. CONCLUSION.....	7

TABLE OF AUTHORITIES

	<u>Page(s)</u>
 Cases	
<i>In re Avandia Mktg., Sales Pracs. & Prod. Liab. Litig.</i> , 924 F.3d 662 (3d Cir. 2019).....	1, 2, 3
<i>Bank of Am. Nat’l Tr. & Sav. Ass’n v. Hotel Rittenhouse Assocs.</i> , 800 F.2d 339 (3d Cir. 1986).....	2
<i>In re Cendant Corp.</i> , 260 F.3d 183 (3d Cir. 2001).....	2
<i>Guardant Health, Inc. v. Foundation Med., Inc.</i> , C.A. No. 17-1616-LPS-CJB, D.I. 447 (D. Del. Jun. 16, 2020)	6
<i>Leucadia, Inc. v. Applied Extrusion Techs., Inc.</i> , 998 F.2d 157 (3d Cir. 1993).....	6
<i>Littlejohn v. Bic Corp.</i> , 851 F.2d 673 (3d Cir. 1988).....	2
<i>Miller v. Indiana Hosp.</i> , 16 F.3d 549 (3d Cir. 1994).....	2
<i>Mosaid Techs. Inc. v. LSI Corp.</i> , 878 F. Supp. 2d 503 (D. Del. 2012).....	2
<i>Nitto Denko Corp. v. Hutchinson Tech. Inc.</i> , C.A. No. 16-3595 (CCC/MF), 2017 WL 2782639 (D.N.J. Mar. 3, 2017)	5
<i>Nixon v. Warner Commc’ns, Inc.</i> , 435 U.S. 589 (1978).....	6
<i>Pansy v. Borough of Stroudsburg</i> , 23 F.3d 772 (3d Cir. 1994).....	2, 6

I. INTRODUCTION

Pursuant to the Protective Order (D.I. 91) as modified by the Court’s November 14, 2023 Order (D.I. 155), Defendants Moderna, Inc. and ModernaTX, Inc. (“Moderna”) respectfully move this Court to seal Moderna’s sensitive and confidential information and to grant leave to file partially redacted versions of Plaintiffs’ Motion to Compel (D.I. 184) and Exhibits 1, 7, and 10-11 thereto. As explained in more detail below, the portions marked for redaction contain Moderna’s sensitive and confidential technical information, including confidential regulatory submissions and trade secrets.

In support of this motion, Moderna attaches as Exhibit A the Declaration of Peter Wojciechowski, CMC Knowledge Management Lead at ModernaTX, Inc., who is knowledgeable about Moderna’s confidential information that Moderna seeks to seal and is familiar with its sensitivity. Moderna seeks to redact portions of Plaintiffs’ Motion and Exhibits 1, 7, and 10-11 thereto (collectively, the “Confidential Materials”).

The Confidential Materials contain Moderna’s highly confidential information, and the Court should maintain that material under seal to prevent serious and real harm to Moderna. Release of Moderna’s highly confidential information to the public and Moderna’s competitors would create a clearly defined and serious injury to Moderna, as discussed in detail below.

II. LEGAL STANDARD

Third Circuit common law presumes a public right of access to judicial records, however it also protects business and financial information when access would cause economic harm, including competitive harm. *In re Avandia Mktg., Sales Pracs. & Prod. Liab. Litig.*, 924 F.3d 662, 672 (3d Cir. 2019). “Although the common law right to public access is a recognized and venerated principle, courts have also recognized the accompanying principle that the right is not

absolute.” *In re Cendant Corp.*, 260 F.3d 183, 194 (3d Cir. 2001) (citations and quotations omitted); *see also Littlejohn v. Bic Corp.*, 851 F.2d 673, 678 (3d Cir. 1988) (“Despite the presumption, courts may deny access to judicial records, for example, where they are sources of business information that might harm a litigant’s competitive standing.”).

This presumption is overcome where a movant shows “that the interest in secrecy outweighs the presumption.” *In re Avandia Mktg.*, 924 F.3d at 672 (quoting *Bank of Am. Nat’l Tr. & Sav. Ass’n v. Hotel Rittenhouse Assocs.*, 800 F.2d 339, 344 (3d Cir. 1986)). This showing may be made by demonstrating that disclosure will work a clearly defined and serious injury to the movant and that the material is the kind of information that courts will protect. *See In re Avandia Mktg.*, 924 F.3d at 672 (citing *Miller v. Indiana Hosp.*, 16 F.3d 549, 551 (3d Cir. 1994)). The Court will apply a “good cause” standard justifying sealing or redacting judicial records, requiring a “balancing process, in which courts weigh the harm of disclosing information against the importance of disclosure to the public.” *Mosaid Techs. Inc. v. LSI Corp.*, 878 F. Supp. 2d 503, 507-08 (D. Del. 2012) (citing *Pansy v. Borough of Stroudsburg*, 23 F.3d 772, 787 (3d Cir. 1994)).

III. ARGUMENT

Good cause exists here to seal the Confidential Materials because the Confidential Materials contain Moderna’s highly confidential technical and business information. Disclosure of such information would cause real and serious competitive harm to Moderna and the information does not need to be disclosed to the public to understand the filings at issue.

Although the public’s presumptive common law right of access to judicial records attaches to materials filed in connection with a pretrial motion of a non-discovery nature, this right is “not absolute” and may be overcome by a showing that the material sought to be sealed

“is the kind of information that courts will protect and ... will work a clearly defined and serious injury to the party seeking closure.” *In re Avandia Mktg.*, 924 at 672 (citation omitted). Here, the Confidential Materials are all the types of limited information of the kind that courts in the Third Circuit have recognized as protectable, namely highly sensitive and confidential technical information regarding Moderna’s proprietary and trade secret manufacturing methods for its COVID-19 Vaccine, including steps in the manufacturing process and parameters for those steps.

The harms caused by revealing Moderna’s confidential information are discussed below, and further in the attached declaration of Peter Wojciechowski (Exhibit A), a CMC Knowledge Management Lead at ModernaTX, Inc., who is familiar with this information and its sensitivity. As Mr. Wojciechowski explains, there is significant competition between established vaccine suppliers, including suppliers with mRNA-based vaccines, like Moderna, and any information about one of these competitors, even seemingly minor information, may prove competitively advantageous. Ex. A, ¶ 7.

Moderna seeks only to partially seal the Confidential Materials at issue in this motion. As described briefly below, and further explained in the Declaration of Peter Wojciechowski, attached hereto as Exhibit A, the Confidential Materials contain Moderna’s confidential information. The Confidential Materials contain highly confidential and sensitive information regarding Moderna’s proprietary technology relating to its manufacturing methods for its COVID-19 Vaccine, known as mRNA-1273 or “SpikeVax.” Ex. A, ¶ 6. SpikeVax is comprised of messenger RNA (mRNA) which is delivered using lipid nanoparticles (LNPs). Ex. A, ¶ 3. Moderna’s proprietary LNP is comprised of four lipid components including SM-102, cholesterol, phospholipid, and PEGDMG-2000. Ex. A, ¶ 3. With respect to Moderna’s

formulation, Moderna considers its precise formulation, including the specific quantities of ingredients, a trade secret, which is not public knowledge. Ex. A, ¶ 8. With respect to Moderna's manufacturing process for SpikeVax, Moderna considers its process-as-a-whole a trade secret, including the steps in the process, the records of each step, the parameters or specification for each step (such as timing, sequence, amount and kind of raw materials, temperatures, measurements, equipment used etc.). Ex. A, ¶ 9. Moderna has not publicly disclosed its proprietary manufacturing process. Ex. A, ¶ 9.

Moderna has not publicly disclosed information within Plaintiffs' Motion and Exhibits 1, 7, and 10-11 which refer to, quote, summarize, or otherwise disclose Moderna's sensitive and confidential technical information. Specifically, the information on the following pages of Moderna's Opposition and Exhibits disclose specific information concerning the composition of Moderna's COVID-19 Vaccine (and other pipeline products) and Moderna's proprietary and trade secret manufacturing methods for its COVID-19 Vaccine (and other pipeline products) including steps in the manufacturing process and parameters for those steps:

- Plaintiffs' Motion at page 1, lines 30-35; page 2, line 19;
- Exhibit 1 at page 9, lines 12-15;
- Exhibit 7 (confidential regulatory filing);
- Exhibit 10 at page 2, lines 6, 13-14; and
- Exhibit 11, page 4, line 11; page 8, lines 4-13; page 11, line 26; page 13, lines 1-4, 12-13.

Because of the highly competitive nature of the vaccine supplier market, Moderna has spent significant effort and resources to develop these manufacturing methods and formulations and the release of such information to the public, including Moderna's competitors, would harm Moderna. Ex. A, ¶ 7. Because there are so few competitors in the vaccine supplier market, the

market is highly competitive, and any information about one of the competitors, even seemingly minor information, may prove competitively advantageous. Ex. A, ¶ 7. Additionally, there are companies considering entering the vaccine market and companies developing mRNA-based vaccines and therapeutics for other diseases or developing lipid nanoparticles for mRNA-based products. Ex. A, ¶ 7.

The Confidential Materials also include highly confidential business information regarding Moderna's COVID-19 Vaccine. Ex. A, ¶ 6. If the confidential information were made public, Moderna's competitors would be able to potentially replicate Moderna's products, features within Moderna's products, and methods of making mRNA-LNP products, or make decisions about where, when, and how to offer directly competitive goods with full knowledge of Moderna's technology. Ex. A, ¶ 10. Moderna's competitors would gain a significant advantage in creating their own business strategies, which would put Moderna at a significant competitive disadvantage, causing it real and serious harm. Ex. A, ¶ 10. Moderna's competitors may also seek patent claims to cover Moderna's technology. Ex. A, ¶ 10.

Moderna has always taken extensive measures to maintain the confidentiality of its technical information. Ex. A, ¶ 5. Moderna has been extremely concerned about the protection of its confidential information during this litigation and has been very careful to always protect this information. Ex. A, ¶ 5. Moderna has invested significant resources to develop this information as well, Ex. A, ¶ 7, and this information is of the type that courts have recognized as protectable. *See, e.g., Nitto Denko Corp. v. Hutchinson Tech. Inc.*, C.A. No. 16-3595 (CCC/MF), 2017 WL 2782639, at *2 (D.N.J. Mar. 3, 2017) (granting motion to seal "confidential technical information" where such information "was not intended to be seen by competitors . . . for review and potential use against the parties" and parties were in a "highly

competitive [] industry”); *Guardant Health, Inc. v. Foundation Med., Inc.*, C.A. No. 17-1616-LPS-CJB, D.I. 447 (D. Del. Jun. 16, 2020) (granting motion to redact confidential information concerning defendant’s confidential technical information).

Disclosure of Moderna’s confidential information regarding either the technical details of Moderna’s precise formulation and the proprietary manufacturing process for SpikeVax would “work a clearly defined and serious injury” to Moderna, as such disclosure would provide Moderna’s competitors, customers, and potential licensors or licensees with otherwise confidential information regarding Moderna’s products and strategies, as well as a competitive advantage in both the vaccine supplier market and in negotiations with Moderna. *See Pansy*, 23 F.3d at 786. Moreover, because this “case involves private litigants” and their confidential information, there is “little legitimate public interest” in the proposed redactions. *Id.* at 788. Under such circumstances, Moderna’s interest in maintaining the confidentiality of the proposed redacted information outweighs any countervailing public interest. *See id.* (“[I]f a case involves private litigants, and concerns matters of little legitimate public interest, that should be a factor weighing in favor of granting or maintaining an order of confidentiality.”); *Leucadia, Inc. v. Applied Extrusion Techs., Inc.*, 998 F.2d 157, 166 (3d Cir. 1993) (“Documents containing trade secrets or other confidential business information may be protected from disclosure” and explaining that the court has “framed the inquiry as whether the need for secrecy outweighs the presumption of access that normally attaches to such documents”); *Nixon v. Warner Commc’ns, Inc.*, 435 U.S. 589, 598 (1978) (“[C]ourts have refused to permit their files to serve as ... sources of business information that might harm a litigant’s competitive standing”).

As explained above, the Confidential Materials identified contain technical details regarding Moderna’s proprietary LNP formulation in SpikeVax and the related proprietary

manufacturing process. Moderna's proposed redactions redact the specific confidential material at issue, leaving the remainder of Plaintiffs' Motion unredacted. These proposed redactions are narrow such that the public's ability to understand the claim construction arguments is not impaired any less than necessary to prevent the release of Moderna's most sensitive technical information to its competitors, preventing clear competitive harm. Moderna's proposed redactions are narrow in scope and refer only to Moderna's confidential, sensitive technical or business information to prevent the serious harm to Moderna which would be caused by its public release as outlined in Mr. Wojciechowski's Declaration. Exhibit 7 to Plaintiffs' Motion is a confidential regulatory submission to the FDA and discloses specific information concerning Moderna's proprietary and trade secret manufacturing methods for its COVID-19 Vaccine including steps in the manufacturing process and parameters for those steps. Likewise, sealing Exhibit 7 does not impair the public's ability to understand the arguments any more than necessary to prevent the release of Moderna's most sensitive technical information to its competitors, preventing clear competitive harm.

IV. CONCLUSION

For the foregoing reasons, Moderna respectfully requests the Court grant Moderna's Motion to Seal with respect to Moderna's highly confidential information.

MORRIS, NICHOLS, ARSHT & TUNNELL LLP

/s/ Travis J. Murray

OF COUNSEL:

Patricia A. Carson, Ph.D.
Jeanna M. Wacker, P.C.
Mark C. McLennan
Caitlin Dean
Nancy Kaye Horstman
Shaoyao Yu
KIRKLAND & ELLIS LLP
601 Lexington Avenue
New York, NY 10022
(212) 446-4800

Alina Afinogenova
KIRKLAND & ELLIS LLP
200 Clarendon Street
Boston, MA 02116
(617) 385-7500

Yan-Xin Li
KIRKLAND & ELLIS LLP
555 California Street, 27th Floor
San Francisco, CA 94104
(415) 439-1400

January 12, 2024

Jack B. Blumenfeld (#1014)
Brian P. Egan (#6227)
Travis J. Murray (#6882)
1201 North Market Street
P.O. Box 1347
Wilmington, DE 19899
(302) 658-9200
jblumenfeld@morrisnichols.com
began@morrisnichols.com
tmurray@morrisnichols.com

Attorneys for Defendants

CERTIFICATE OF SERVICE

I hereby certify that on January 12, 2024, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF, which will send notification of such filing to all registered participants.

I further certify that I caused copies of the foregoing document to be served on January 12, 2024, upon the following in the manner indicated:

John W. Shaw, Esquire
Karen E. Keller, Esquire
Nathan R. Hoeschen, Esquire
Emily S. DiBenedetto, Esquire
SHAW KELLER LLP
I.M. Pei Building
1105 North Market Street, 12th Floor
Wilmington, DE 19801
*Attorneys for Plaintiffs Arbutus Biopharma
Corporation and Genevant Sciences GmbH*

VIA ELECTRONIC MAIL

Daralyn J. Durie, Esquire
Adam R. Brausa, Esquire
Eric C. Wiener, Esquire
Annie A. Lee, Esquire
Shaelyn K. Dawson, Esquire
MORRISON & FOERSTER LLP
425 Market Street
San Francisco, CA 94105-2482
*Attorneys for Plaintiff Arbutus Biopharma
Corporation*

VIA ELECTRONIC MAIL

Kira A. Davis, Esquire
MORRISON & FOERSTER LLP
707 Wilshire Boulevard
Los Angeles, CA 90017-3543
*Attorneys for Plaintiff Arbutus Biopharma
Corporation*

VIA ELECTRONIC MAIL

David N. Tan, Esquire
MORRISON & FOERSTER LLP
2100 L Street, NW, Suite 900
Washington, DC 20037
Attorneys for Plaintiff Arbutus Biopharma Corporation

VIA ELECTRONIC MAIL

David I. Berl, Esquire
Adam D. Harber, Esquire
Thomas S. Fletcher, Esquire
Jessica Palmer Ryen, Esquire
Shaun P. Mahaffy, Esquire
Anthony H. Sheh, Esquire
Philip N. Haunschild, Esquire
Jihad J. Komis, Esquire
Matthew W. Lachman, Esquire
WILLIAMS & CONNOLLY LLP
680 Maine Avenue S.W.
Washington, DC 20024
Attorneys for Plaintiff Genevant Sciences GmbH

VIA ELECTRONIC MAIL

/s/ Travis J. Murray

Travis J. Murray (#6882)